Abstract library

153 results for "Mitotic Count".
#2129 Phosphohistone H3 (PHH3) Immunohistochemical Staining Outperforms Conventional H&E Mitotic Count in Classifying Pulmonary Carcinoids
Introduction: Pulmonary carcinoids (PC) are well-differentiated NETs and are classified as typical carcinoid (TC) and atypical carcinoid (AC). Despite the fact that TC and AC exhibit significant differences in patient survival, their classification depends on relatively subtle differences in mitotic count (MC). Although careful counting of mitotic figures (MF) is essential, it is a very subjective task, time-consuming and lacks of sensitivity and interobserver reproducibility, due to selection bias of the hot spots, heterogeneous distribution of MF, difficulty in distinguishing MF from similar chromatin changes (i.e. in apoptotic cells or due to crush, karyorrhectic debris, pyknosis or apoptosis).
Conference: 15th Annual ENETS conference (2018)
Category: Pathology - grading, staging
Presenting Author: Dr Tu Vinh Luong
#129 Grade according to Ki-67 or mitotic count in gastroenteropancreatic neuroendocrine tumors
Introduction: Gastroenteropancreatic neuroendocrine tumors (NETs) are uncommon tumors with a reported incidence of 2.5-5 per 100000 population. The recent classification system of NETs proposed by the European Neuroendocrine Tumor Society (ENETS) uses both Ki-67 labelling index and mitotic index to assign grade (low, intermediate, high). It has been adopted into routine practice but there is limited data on the relationship between these indices and their effect on classification.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Mohid S Khan
#251 Ki-67 is a Better Prognostic Marker than Mitotic Count in Neuroendocrine Tumors
Introduction: The recent classification system proposed by ENETS assigns grade by Ki-67 index +/- mitotic count. It has been adopted into routine practice but there is limited data on the relationship between them.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Mohid S Khan
#935 A Three Tier Grading System Based on Ki-67 Index, Mitotic Count and Necrosis with Cut-Offs Specifically Generated for Lung Neuroendocrine Tumors is Prognostically Effective and Accurate
Introduction: Lung neuroendocrine tumors are catalogued into four categories by the World Health Organization (WHO 2004) classification. Its reproducibility and prognostic efficacy was disputed. The WHO 2010 classification of digestive neuroendocrine neoplasms is based on a Ki-67 index and has proved prognostically effective.
Conference: 11th Annual ENETS Conference (2014)
Category: Pathology, grading, staging
Presenting Author: Professor Guido Rindi
Authors: Rindi G, Klersy C, Inzani F, ...
#737 Impact of Ki-67 Proliferative Index on Survival in Patients with Typical and Atypical Pulmonary Carcinoids
Introduction: Currently pulmonary carcinoids are separated into typical and atypical tumors based on mitotic count and presence of necrosis, according to the WHO classification. Whereas for GEP NETs the ENETS Guidelines have been incorporated into the WHO classification and grading is based on mitotic counts and Ki-67 index, the use of the Ki-67 index for grading pulmonary carcinoids is still under debate.
Conference: 10th Annual ENETS Conference (2013)
Category: Surgical treatment
Presenting Author: Dr Martina Rudelius
#813 Comparison of Manual and Automatic Methods of Ki-67 Proliferation Index for Neuroendocrine Tumors: The Development and Validation of a Novel Digital Pathology Tool (Ki-67Counter)
Introduction: Ki-67 proliferation index is an increasingly important biomarker used to grade neuroendocrine tumors. Manual counting methods are laborious and subject to inter- and intra-observer variability. Digital counting methods hold promise for fast and reproducible indices, however, they are fraught with technical difficulties.
Conference: 11th Annual ENETS Conference (2014)
Category: Pathology, grading, staging
Presenting Author: Dr. Lin Yang
Authors: Neltner J, Su H, Xing F, Rosser J, ...
#1595 Pathological Features of High Proliferative Activity Neuroendocrine Tumor
Introduction: High Proliferative Activity Neuroendocrine Tumor (NET G3) is difficult to be distinguished from neuroendocrine carcinoma. However, there are differences in clinical treatment and prognosis between the two. So it is crucial to make an accurate pathological diagnosis.
Conference: 14th Annual ENETS conference (2017)
Category: Pathology, grading, staging
Presenting Author: Huilin Geng
Authors: Geng H, Shi S, ...
#896 Grading of Metastases in Digestive Neuroendocrine Tumors (NET): Interest for Clinical Management?
Introduction: Therapeutic strategy of NETs is highly dependent on tumor classification according to the WHO system. NETs are frequently classified based on the histological characteristics of the primary tumor associated with the ENETS grading, even for patients with metastases.
Conference: 11th Annual ENETS Conference (2014)
Category: Pathology, grading, staging
Presenting Author: Dr Marie-Françoise Heymann
Keywords: NET, grading
#1104 Interlaboratory Variability of MIB1 Staining in Well Differentiated Pancreatic Neuroendocrine Tumors
Introduction: In neuroendocrine tumors (NET) grading and staging are the only routinely performed procedures to judge prognosis. Proliferation index using MIB1 staining has been introduced to assess grading. There are discussions on cut-off definitions, automated counting and inter-observer variability.
Conference: 12th Annual ENETS Conference (2015)
Category: Pathology, grading, staging
Presenting Author: Dr. Blank Annika
Authors: Blank A, Wehweck L, Marinoni I, Boos L, ...
Keywords: MIB1, Ki67, grading, NET
#368 The Role of Image and Chromogranin A Level at Diagnosis: A Portuguese Review of 19 Patients
Introduction: Neuroendocrine tumors (NET) constitute a heterogeneous group of neoplasms. Biochemical neuroendocrine markers offer high sensitivity in establishing the diagnosis and, if correlated with image assessment, can provide important prognostic information.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Pedro Barata